Search
Close this search box.

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies

Print Friendly, PDF & Email

Ardini E, Siena S
ESMO Open. 2020 Sep;5(5):e000867. doi: 10.1136/esmoopen-2020-000867. PMID: 32907817; PMCID:PMC7481078.

Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas
Nerviano MS Logo

Follow Us on

Nerviano Medical Sciences S.r.l. 

Viale Luigi Pasteur 10
20014 Nerviano (MI)
Italy

Share Capital: € 1,200,000.00
fully paid-in

Company subject to the management and coordination of NMS Group S.p.A.

Copyright © 2020 Nerviano Medical Sciences S.r.l
Website by Axxiem

Share this page

Facebook
Twitter
LinkedIn
Email
svg.e-font-icon-svg {display:none!important} .elementor-button-icon {display:none!important} .show-more, .show-more2 {display:none!important} img.pf-large-image.pf-primary-img.flex-width.pf-size-full.blockImage { display: none!important; }